001009716 001__ 1009716
001009716 005__ 20231215103721.0
001009716 0247_ $$2doi$$a10.3389/fpsyt.2023.1228438
001009716 0247_ $$2datacite_doi$$a10.34734/FZJ-2023-02948
001009716 0247_ $$2pmid$$a37520217
001009716 0247_ $$2WOS$$aWOS:001035260100001
001009716 037__ $$aFZJ-2023-02948
001009716 082__ $$a610
001009716 1001_ $$0P:(DE-Juel1)131691$$aKroll, Tina$$b0$$eCorresponding author$$ufzj
001009716 245__ $$aEffects of electroconvulsive therapy on cerebral A1 adenosine receptor availability: a PET study in patients suffering from treatment-resistant major depressive disorder
001009716 260__ $$aLausanne$$bFrontiers Research Foundation$$c2023
001009716 3367_ $$2DRIVER$$aarticle
001009716 3367_ $$2DataCite$$aOutput Types/Journal article
001009716 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1695966516_23063
001009716 3367_ $$2BibTeX$$aARTICLE
001009716 3367_ $$2ORCID$$aJOURNAL_ARTICLE
001009716 3367_ $$00$$2EndNote$$aJournal Article
001009716 520__ $$aSleep deprivation and electroconvulsive therapy (ECT) effectively ameliorate symptoms in major depressive disorder (MDD). In rodents, both are associated with an enhancement of cerebral adenosine levels, which in turn likely influence adenosinergic receptor expression. The aim of the current study was to investigate cerebral A1 adenosine receptor (A1AR) availability in patients with MDD as a potential mediating factor of antidepressant effects of ECT using [18F]CPFPX and positron emission tomography (PET).Regional A1AR availability was determined before and after a series of ECT applications (mean number ± SD 10.4 ± 1.2) in 14 subjects (4 males, mean age 49.5 ± 11.8 years). Clinical outcome, measured by neuropsychological testing, and ECT parameters were correlated with changes in A1AR availability.ECT had a strong antidepressive effect (p < 0.01) while on average cerebral A1AR availability remained unaltered between pre-and post-ECT conditions (F = 0.65, p = 0.42, mean difference ± SD 3.93% ± 22.7%). There was no correlation between changes in clinical outcome parameters and regional A1AR availability, although individual patients showed striking bidirectional alterations of up to 30–40% in A1AR availability after ECT. Solely, for the mean seizure quality index of the applied ECTs a significant association with changes in A1AR availability was found (rs = −0.6, p = 0.02).In the present study, therapeutically effective ECT treatment did not result in coherent changes of A1AR availability after a series of ECT treatments. These findings do not exclude a potential role for cerebral A1ARs in ECT, but shift attention to rather short-termed and adaptive mechanisms during ECT-related convulsive effects.
001009716 536__ $$0G:(DE-HGF)POF4-5252$$a5252 - Brain Dysfunction and Plasticity (POF4-525)$$cPOF4-525$$fPOF IV$$x0
001009716 536__ $$0G:(DE-HGF)POF4-5253$$a5253 - Neuroimaging (POF4-525)$$cPOF4-525$$fPOF IV$$x1
001009716 588__ $$aDataset connected to CrossRef, Journals: juser.fz-juelich.de
001009716 7001_ $$0P:(DE-HGF)0$$aGrözinger, Michael$$b1
001009716 7001_ $$0P:(DE-Juel1)138474$$aMatusch, Andreas$$b2$$ufzj
001009716 7001_ $$0P:(DE-Juel1)131679$$aElmenhorst, David$$b3$$ufzj
001009716 7001_ $$0P:(DE-HGF)0$$aNovakovic, Ana$$b4
001009716 7001_ $$0P:(DE-Juel1)171785$$aSchneider, Frank$$b5
001009716 7001_ $$0P:(DE-Juel1)131672$$aBauer, Andreas$$b6$$ufzj
001009716 773__ $$0PERI:(DE-600)2564218-2$$a10.3389/fpsyt.2023.1228438$$gVol. 14, p. 1228438$$p1228438$$tFrontiers in psychiatry$$v14$$x1664-0640$$y2023
001009716 8564_ $$uhttps://juser.fz-juelich.de/record/1009716/files/fpsyt-14-1228438.pdf$$yOpenAccess
001009716 8767_ $$d2023-08-28$$eAPC$$jDeposit$$z2741,25 $
001009716 909CO $$ooai:juser.fz-juelich.de:1009716$$pdnbdelivery$$popenCost$$pVDB$$pdriver$$pOpenAPC$$popen_access$$popenaire
001009716 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)131691$$aForschungszentrum Jülich$$b0$$kFZJ
001009716 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)138474$$aForschungszentrum Jülich$$b2$$kFZJ
001009716 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)131679$$aForschungszentrum Jülich$$b3$$kFZJ
001009716 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)131672$$aForschungszentrum Jülich$$b6$$kFZJ
001009716 9131_ $$0G:(DE-HGF)POF4-525$$1G:(DE-HGF)POF4-520$$2G:(DE-HGF)POF4-500$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$9G:(DE-HGF)POF4-5252$$aDE-HGF$$bKey Technologies$$lNatural, Artificial and Cognitive Information Processing$$vDecoding Brain Organization and Dysfunction$$x0
001009716 9131_ $$0G:(DE-HGF)POF4-525$$1G:(DE-HGF)POF4-520$$2G:(DE-HGF)POF4-500$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$9G:(DE-HGF)POF4-5253$$aDE-HGF$$bKey Technologies$$lNatural, Artificial and Cognitive Information Processing$$vDecoding Brain Organization and Dysfunction$$x1
001009716 9141_ $$y2023
001009716 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2022-11-26
001009716 915__ $$0LIC:(DE-HGF)CCBY4$$2HGFVOC$$aCreative Commons Attribution CC BY 4.0
001009716 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2021-05-12T10:47:58Z
001009716 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2021-05-12T10:47:58Z
001009716 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2022-11-26
001009716 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2022-11-26
001009716 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
001009716 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2022-11-26
001009716 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Anonymous peer review$$d2021-05-12T10:47:58Z
001009716 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bFRONT PSYCHIATRY : 2022$$d2023-10-26
001009716 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-10-26
001009716 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-10-26
001009716 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2023-10-26
001009716 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-10-26
001009716 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-10-26
001009716 915__ $$0StatID:(DE-HGF)1180$$2StatID$$aDBCoverage$$bCurrent Contents - Social and Behavioral Sciences$$d2023-10-26
001009716 915__ $$0StatID:(DE-HGF)0130$$2StatID$$aDBCoverage$$bSocial Sciences Citation Index$$d2023-10-26
001009716 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2023-10-26
001009716 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2023-10-26
001009716 915pc $$0PC:(DE-HGF)0000$$2APC$$aAPC keys set
001009716 915pc $$0PC:(DE-HGF)0001$$2APC$$aLocal Funding
001009716 915pc $$0PC:(DE-HGF)0002$$2APC$$aDFG OA Publikationskosten
001009716 915pc $$0PC:(DE-HGF)0003$$2APC$$aDOAJ Journal
001009716 920__ $$lyes
001009716 9201_ $$0I:(DE-Juel1)INM-2-20090406$$kINM-2$$lMolekulare Organisation des Gehirns$$x0
001009716 980__ $$ajournal
001009716 980__ $$aVDB
001009716 980__ $$aUNRESTRICTED
001009716 980__ $$aI:(DE-Juel1)INM-2-20090406
001009716 980__ $$aAPC
001009716 9801_ $$aAPC
001009716 9801_ $$aFullTexts